Nakhle S. Saba

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

Mohammed Farooqui, Janet Valdez, Sabrina Martyr et al. · The Lancet Oncology · 2014 · 366 citations · Full text

Medicine, Immunology, Oncology +11

A smartphone-read ultrasensitive and quantitative saliva test for COVID-19

Bo Ning, Tao Yu, Shengwei Zhang et al. · Science Advances · 2021 · 249 citations · Full text

Medicine, Infectious Diseases, Molecular Biology +17

Auranofin Induces Lethal Oxidative and Endoplasmic Reticulum Stress and Exerts Potent Preclinical Activity against Chronic Lymphocytic Leukemia

Warren Fiskus, Nakhle S. Saba, Min Shen et al. · Cancer Research · 2014 · 246 citations · Full text

Medicine, Oncology, Pharmacology +15

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Inhye E. Ahn, Mohammed Farooqui, Xin Tian et al. · Blood · 2018 · 204 citations · Full text

Medicine, Pharmacology, Pharmacodynamics +4

Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study

Sarah E. M. Herman, Carsten Utoft Niemann, Mahfooz Farooqui et al. · Leukemia · 2014 · 190 citations · Full text

Medicine, Hematology, Oncology +15